Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURF302: TYRA-300 in FGFR3-altered intermediate-risk non–muscle invasive bladder cancer
2025-521277-14-00Phase 2Authorised
- Sponsor
- Tyra Biosciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of dabogratinib in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Tyra Biosciences. Primary endpoint: Complete response rate at 3 months. Planned start Oct 2025; status: authorised.
02
Drugs
dabogratinib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2025-521277-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521277-14-00.